Johnson & Johnson is making its biggest investment yet in “in vivo” cell therapy, announcing late Wednesday a deal to work with, and potentially acquire, young biotechnology firm Sail Biomedicines at an agreed-upon price. J&J is paying $785 million up front initially, including a $465 million equity investment, to help advance Sail’s lead program as well as a technology the startup uses to reprogram immune cells inside the body. Dubbed SAIL-0839, that prospect is still in preclinical testing, and Sail hasn’t disclosed what diseases it will go after. Other therapeutic targets could be added to the deal over time, J&J said. J&J has also secured an exclusive option to acquire the startup for $2.58 billion in the future.
Read the full article: J&J Nabs Option to Buy ‘In Vivo’ CAR-T Maker Sail for Nearly $2.6B //
Source: https://www.biopharmadive.com/news/johnson-johnson-sail-option-acquire-in-vivo-car-t/826589/